Werewolf Therapeutics Inc’s recent filing unveils that its Director EVNIN LUKE unloaded Company’s shares for reported $57205.0 on Nov 13 ’25. In the deal valued at $0.98 per share,58,372 shares were sold. As a result of this transaction, EVNIN LUKE now holds 3,592,061 shares worth roughly $3.3 million.
Then, EVNIN LUKE sold 39,560 shares, generating $36,791 in total proceeds. Upon selling the shares at $0.93, the Director now owns 3,552,501 shares.
Before that, EVNIN LUKE sold 36,621 shares. Werewolf Therapeutics Inc shares valued at $34,790 were divested by the Director at a price of $0.95 per share. As a result of the transaction, EVNIN LUKE now holds 3,515,880 shares, worth roughly $3.23 million.
JMP Securities initiated its Werewolf Therapeutics Inc [HOWL] rating to a Mkt outperform in a research note published on April 03, 2024; the price target was $12. A number of analysts have revised their coverage, including Wedbush’s analysts, who began to cover the stock in late August with a ‘”an Outperform”‘ rating. BofA Securities started covering the stock on September 10, 2021. It rated HOWL as “a Buy”.
Price Performance Review of HOWL
On Monday, Werewolf Therapeutics Inc [NASDAQ:HOWL] saw its stock jump 0.13% to $0.92. Over the last five days, the stock has lost -20.74%. Werewolf Therapeutics Inc shares have fallen nearly -55.15% since the year began. Nevertheless, the stocks have fallen -37.88% over the past one year. While a 52-week high of $2.38 was reached on 09/29/25, a 52-week low of $0.60 was recorded on 04/07/25.
Levels Of Support And Resistance For HOWL Stock
The 24-hour chart illustrates a support level at 0.8903, which if violated will result in even more drops to 0.8611. On the upside, there is a resistance level at 0.9742. A further resistance level may holdings at 1.0289.
How much short interest is there in Werewolf Therapeutics Inc?
A steep rise in short interest was recorded in Werewolf Therapeutics Inc stocks on 2025-10-31, growing by 47042.0 shares to a total of 0.9 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-30 was 0.86 million shares. There was a rise of 5.21%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on May 25, 2021 when SVB Leerink began covering the stock and recommended ‘”an Outperform”‘ rating along with a $29 price target.
